Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Centre for Addiction and Mental Health |
---|---|
Information provided by: | Centre for Addiction and Mental Health |
ClinicalTrials.gov Identifier: | NCT00736710 |
Patients with schizophrenia have high rates of cigarette smoking and tobacco dependence, and great difficulties in quitting smoking. The development of novel and more effective treatments for tobacco dependence in this population is thus needed. This study will test the hypothesis that repetitive transcranial magnetic stimulation (rTMS) may facilitate smoking cessation with the transdermal nicotine patch (TNP) in patients with schizophrenia motivated to quit smoking. A total of N=40 smokers with schizophrenia would be assigned to either active rTMS (N=20) or sham rTMS (N=20) as a treatment regimen of 5X/week treatments for four weeks. All subjects would receive TNP (21 mg/24h) and weekly group behavioral therapy for smoking cessation for a total of 10 weeks. We predict that active rTMS will be well-tolerated and superior to sham rTMS for enhancing smoking cessation rates in smokers with schizophrenia.
Condition | Intervention |
---|---|
Cigarette Smoking Schizophrenia |
Procedure: Repetitive Transcranial Magnetic Stimulation (rTMS) Procedure: Sham Repetitive Transcranial Magnetic Stimulation (rTMS) |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study |
Official Title: | Effects of rTMS on Smoking Cessation and Cognitive Outcomes in Outpatients With Schizophrenia Treated With Transdermal Nicotine Patch |
Estimated Enrollment: | 40 |
Study Start Date: | December 2008 |
Estimated Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Procedure: Repetitive Transcranial Magnetic Stimulation (rTMS)
The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
|
2: Sham Comparator |
Procedure: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
|
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Tony George, MD | 416-535-8501 ext 4544 | tony_george@camh.net |
Canada, Ontario | |
Centre for Addiction and Mental Health | Recruiting |
Toronto, Ontario, Canada, M5S 2S1 | |
Principal Investigator: Tony George, MD | |
Sub-Investigator: Zafiris J Daskalakis, MD, PhD | |
Sub-Investigator: Eleanor Liu | |
Sub-Investigator: Gloria Leo |
Principal Investigator: | Tony George, MD | Centre for Addiction and Mental Health |
Responsible Party: | Centre for Addiction and Mental Health ( Tony George, MD ) |
Study ID Numbers: | 121/2007 |
Study First Received: | August 15, 2008 |
Last Updated: | February 18, 2009 |
ClinicalTrials.gov Identifier: | NCT00736710 History of Changes |
Health Authority: | Canada: Health Canada |
Repetitive Transcranial Magnetic Stimulation Cigarette smoking Schizophrenia Randomized |
Double-blind Placebo-controlled longitudinal nicotine patch |
Nicotine polacrilex Schizophrenia Smoking Neurotransmitter Agents Nicotine Mental Disorders |
Nicotinic Agonists Psychotic Disorders Peripheral Nervous System Agents Cholinergic Agents Schizophrenia and Disorders with Psychotic Features |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Cholinergic Agonists Nicotinic Agonists Physiological Effects of Drugs Cholinergic Agents Pharmacologic Actions Schizophrenia |
Smoking Habits Mental Disorders Nicotine Autonomic Agents Ganglionic Stimulants Peripheral Nervous System Agents Schizophrenia and Disorders with Psychotic Features |